Status:
COMPLETED
Ghrelin and Insulin Resistance
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Obesity
Insulin Resistance
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Ghrelin, a hormone produced in the stomach that stimulates hunger and food intake, declines immediately after weight loss surgery. Some studies suggest that ghrelin may worsen an individual's ability ...
Eligibility Criteria
Inclusion
- Inclusion Criteria for RYGB group:
- Age 18-65
- BMI \> 35 kg/m2
- Scheduled for bariatric surgery at Vanderbilt University Medical Center
- Inclusion Criteria for Lean group:
- Age 18-65
- BMI \< 30kg/m2
- Exclusion Criteria:
- Prior bariatric surgery
- Serum creatinine \> 1.5 mg/dl
- Hepatic enzyme elevations \> 2x upper limits of normal
- Current use of warfarin or clopidogrel
- Intercurrent infections
- Females with positive pregnancy test
- Abnormal ECG
Exclusion
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00884494
Start Date
August 1 2011
End Date
May 1 2014
Last Update
January 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232